# Beyond Conventional Anti-TIGIT: HanchorBio Secures Taiwan TFDA Approval for HCB303 Following U.S. FDA Clearance

- Source: PR Newswire M&A
- Published: 2026-10-30T13:47:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/beyond-conventional-anti-tigit-hanchorbio-secures-taiwan-tfda-approval-for-hcb303-following-us-fda-clearance-302924982.html
- Canonical: https://groundlevelnews.com/story/beyond-conventional-anti-tigit-hanchorbio-secures-taiwan-tfda-approval-506165/

Differentiated trispecific TIGIT-Fc ligand-trap strategy aims to address CD226 downregulation, a potential limitation of conventional anti-TIGIT antibodies U.S FDA clearance followed by accelerated Taiwan TFDA approval advances HCB303 toward multi-regional Phase 1 clinical development...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._